| [1] |
Rhee C, Klompas M. New sepsis and septic shock definitions: clinical implications and controversies[J]. Infect Dis Clin North Am,2017,31(3):397-413.
|
| [2] |
Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis[J]. Semin Immunopathol,2017,39(5):517-528.
|
| [3] |
Shankar-Hari M, Ambler M, Mahalingasivam V, et al. Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies[J]. Crit Care,2016,20(1):1-13.
|
| [4] |
Lin JC, Spinella PC, Fitzgerald JC, et al. New or progressive multiple organ dysfunction syndrome in pediatric severe sepsis: A sepsis phenotype with higher morbidity and mortality[J]. Pediatr Crit Care Med,2017,18(1):8-16.
|
| [5] |
Wei Y, Yang J, Wang J, et al. Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis[J]. Crit Care,2016,20(1):332-340.
|
| [6] |
Wang B, Chen G, Zhang J, et al. Increased neutrophil gelatinase-associated lipocalin is associated with mortality and multiple organ dysfunction syndrome in severe sepsis and septic shock[J]. Shock,2015,44(3):234-238.
|
| [7] |
Gómez H, Kellum JA, Ronco C. Metabolic reprogramming and tolerance during sepsis-induced AKI[J]. Nat Rev Nephrol,2017,13(3):143-151.
|
| [8] |
Burger D, Erdbrügger U, Burns KD. Re: Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI[J]. Kidney Int,2015,88(4):915-916.
|
| [9] |
Emlet DR, Shaw AD, Kellum JA. Sepsis-associated AKI: epithelial cell dysfunction[J]. Semin Nephrol,2015,35(1):85-95.
|
| [10] |
Godin M, Murray P, Mehta RL. Clinical approach to the patient with AKI and sepsis[J]. Semin Nephrol,2015,35(1):12-22.
|
| [11] |
Shao Y, Fan Y, Xie Y, et al. Effect of continuous renal replacement therapy on kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in patients with septic acute kidney injury[J]. Exp Ther Med,2017,13(6):3594-3602.
|
| [12] |
Ueno T. The roles of continuous renal replacement therapy in septic acute kidney injury[J]. Artif Organs,2017,41(7):667-672.
|
| [13] |
Leifer CA, Medvedev AE. Molecular mechanisms of regulation of Toll-like receptor signaling[J]. J Leukoc Biol,2016,100(5):927-941.
|
| [14] |
Sestito SE, Facchini FA, Morbioli I, et al. Amphiphilic guanidinocalixarenes inhibit lipopolysaccharide (LPS)- and lectin-stimulated Toll-like receptor 4 (TLR4) signaling[J]. J Med Chem,2017,60(12):4882-4892.
|
| [15] |
Li N, Zhang X, Dong H, et al. Lithium ameliorates LPS-induced astrocytes activation partly via inhibition of Toll-Like receptor 4 expression[J]. Cell Physiol Biochem,2016,38(2):714-725.
|
| [16] |
Lang Y, Jiang Y, Gao M, et al. Interleukin-1 receptor 2: A new biomarker for sepsis diagnosis and Gram-negative/Gram-positive bacterial differentiation[J]. Shock,2017,47(1):119-124.
|
| [17] |
Kurt AN, Aygun AD, Godekmerdan A, et al. Serum IL-1-beta, IL-6, IL-8, and TNF-alpha levels in early diagnosis and management of neonatal sepsis[J]. Mediators Inflamm,2007,2007:31397.
|
| [18] |
Johnson DW, Kalil AC. Is interleukin-1 receptor blockade ready for prime time in patients with severe sepsis and macrophage activation syndrome?[J]. Crit Care Med,2016,44(2):443-444.
|
| [19] |
Yang SK, Liu J, Zhang XM, et al. Diagnostic accuracy of serum cystatin C for the evaluation of renal dysfunction in diabetic patients: A Meta-analysis[J]. Ther Apher Dial,2016,20(6):579-587.
|
| [20] |
Leem AY, Park MS, Park BH, et al. Value of serum cystatin C measurement in the diagnosis of sepsis-induced kidney injury and prediction of renal function recovery[J]. Yonsei Med J,2017,58(3):604-612.
|